Any current/future new fundraising through debt or equity?

There is no mention of any current or planned fundraising through debt or equity in the provided transcript. The discussion primarily focuses on operational performance, FDA observations, new product launches, and guidance on revenue and margins. No specific comments or guidance about raising capital via debt or equity instruments were made by management during the call.

Future growth expectations in sales/revenue/volumes?

Domestic business growth expected at 11%-12% for the full year FY '24, improving from 6.6% in Q1. Emerging Markets: Q1 de-growth seen as one-off; strong order book signals a dramatic turnaround from Q2 onwards. API business: Strong Q1 growth with expectations to sustain momentum throughout the year. Europe: Growth expected to pick up in subsequent quarters with recent EU GMP certification and larger batch sizes. US market: Full-year revenue guidance remains INR280-300 crores despite OAI; ramp-up gradual with new launches and increased production aimed at reaching INR80 crores per quarter by Q3

Future growth expectations in earnings/operating earnings/profits/EPS?

Indoco Remedies expects domestic business growth of 11%-12% for FY 2024, an improvement from 6.6% in Q1. EBITDA margin guidance is maintained at around 17%-18% for the full year. US revenue guidance is INR 280-300 crores for FY 2024, with estimated ramp-up from INR 50 crores in Q1 to ~INR 80 crores per quarter in later quarters, driven by new launches and increased production. EBITDA for Q1 was at 15.2% of sales; the company aims for margin improvement through gross margin initiatives and operational efficiencies. API business showed strong growth (169.2% in Q1) and is expected to sustain mome

Current/ Expected Orderbook/ Pending Orders?

The order book for Europe and UK is described as "very, very strong" following EU and UK approvals for manufacturing plants in Baddi. Emerging markets experienced a "one-off" weak quarter, but the order book there is also very strong, with expectations of a dramatic turnaround starting Q2. In the US, despite challenges caused by an OAI, the company anticipates new launches and ramp-up of current products, supporting revenue growth. Overall, the management expresses confidence in a robust demand pipeline across key markets supported by regulatory clearances and expanded capacities.

IN US

Sale is live|00:00:00left today

Indoco Remedies LtdQ2 FY23Pharmaceuticals & Biotechnology

Indoco Remedies Ltd Q2 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹237Market Cap: ₹2.1K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→Domestic business growth expected at 11%-12% for the full year FY '24, improving from 6.6% in Q1.
→Emerging Markets: Q1 de-growth seen as one-off; strong order book signals a dramatic turnaround from Q2 onwards.
→API business: Strong Q1 growth with expectations to sustain momentum throughout the year.
→Europe: Growth expected to pick up in subsequent quarters with recent EU GMP certification and larger batch sizes.
→US market: Full-year revenue guidance remains INR280-300 crores despite OAI; ramp-up gradual with new launches and increased production aimed at reaching INR80 crores per quarter by Q3-Q4.
→New product launches in domestic and chronic therapies contributed INR6.5 crores sales in Q1, more than double last year.
→Anti-infective and respiratory segments are still normalizing post-COVID with cautious outlook.

Margin guidance

Category 3

→Indoco Remedies expects domestic business growth of 11%-12% for FY 2024, an improvement from 6.6% in Q1.
→EBITDA margin guidance is maintained at around 17%-18% for the full year.
→US revenue guidance is INR 280-300 crores for FY 2024, with estimated ramp-up from INR 50 crores in Q1 to ~INR 80 crores per quarter in later quarters, driven by new launches and increased production.
→EBITDA for Q1 was at 15.2% of sales; the company aims for margin improvement through gross margin initiatives and operational efficiencies.
→API business showed strong growth (169.2% in Q1) and is expected to sustain momentum.
→Emerging markets likely to rebound strongly from Q2 onwards after a one-off weak Q1.
→Profit after tax margin stood at 6.2% in Q1, with management confident of improving overall profitability leveraging new product launches and operational efficiencies.

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no mention of any current or planned fundraising through debt or equity in the provided transcript.
→The discussion primarily focuses on operational performance, FDA observations, new product launches, and guidance on revenue and margins.
→No specific comments or guidance about raising capital via debt or equity instruments were made by management during the call.

Order book

Yes

→The order book for Europe and UK is described as "very, very strong" following EU and UK approvals for manufacturing plants in Baddi.
→Emerging markets experienced a "one-off" weak quarter, but the order book there is also very strong, with expectations of a dramatic turnaround starting Q2.
→In the US, despite challenges caused by an OAI, the company anticipates new launches and ramp-up of current products, supporting revenue growth.
→Overall, the management expresses confidence in a robust demand pipeline across key markets supported by regulatory clearances and expanded capacities.

Capex plans

Yes

- The transcript does not explicitly mention any specific current or future capex or strategic investments. - There is mention of digitization efforts, including Apple iPads for field force, AIML projects for machine automation, document management, and HRMS systems to improve efficiency. - The company acquired Florida Pharmaceutical Products (FPP), a US-based front-end distribution and marketing company, consolidated for one month in this quarter. - The company plans to leverage the FPP acquisition for front-ending some products currently with external partners, aiming for a transition within 3-4 months. - Remediation costs related to FDA observations on Plant 2 and 3 in Goa are ongoing, estimated around INR4 crores per quarter. - No explicit mention of new capital expenditure plans, but focus on expanding manufacturing capabilities with increased batch sizes post EU GMP certification at Baddi plant and product launches from Goa Plant 1 post-warning letter lift. Overall, focus is on strategic acquisitions, digitization, and regulatory compliance investments rather than new large capex.

How does Indoco Remedies Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Indoco Remedies Ltd

Rev 3Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Indoco Remedies Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio